Drug Trial Radar · NCT00055991
Bexarotene in Preventing Breast Cancer in Women at Genetic Risk
Last checked: Nov 20, 2026Latest source record: Feb 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Sep 2001
Primary completion
Sep 2006
Study completion Sep 2006
Sponsor
- Lead sponsor
- Baylor Breast Care CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Mar 7, 2003
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Chemoprevention therapy uses certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether bexarotene is effective in preventing breast cancer. PURPOSE: Randomized clinical trial to study the effectiveness of bexarotene in preventing breast cancer in women who are at genetic risk of developing breast cancer.
Conditions
- Breast Cancer
Interventions
bexaroteneDrug
This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Chemopreventive effect as determine by a modification of the immunophenotypic characteristics of normal breast tissue at day 29 during study treatment and day 30 after study completion
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia
M.D. Anderson Cancer Center at University of Texas
Houston, Texas
Dan L. Duncan Cancer Center at Baylor College of Medicine
Houston, Texas
Cancer Therapy and Research Center
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.